Corvus Pharmaceuticals, Inc. (CRVS)
$10.05-4.47%Close
SELLCRISIS · day 13
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $845M
- Beta
- 0.86
- P/E (TTM)
- -14.70
- Short % float
- 24.46%
- Days to cover
- 13.3
- SI change
- +3.6%
- 1W
- -6.42%
- 1M
- -22.15%
- vs SPY 1W
- -6.85%
- vs SPY 1M
- -24.21%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on CRVS?
- LOPJLB’s latest quantitative signal on Corvus Pharmaceuticals, Inc. (CRVS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CRVS in?
- Corvus Pharmaceuticals, Inc. (CRVS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Corvus Pharmaceuticals, Inc. (CRVS) do?
- Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another …